An in vitro model for preclinical testing of endocrine therapy combinations for prostate cancer

Prostate

Volumn 70, Issue 14, 2010, Pages 1524-1532

  Pfeiffer, Minja J ^a   Mulders, Peter F ^a   Schalken, Jack A ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Androgen metabolism; Androgen receptor; DuCaP; DuCaP N

Indexed keywords

ANDROGEN RECEPTOR; ANTIANDROGEN; BICALUTAMIDE; FINASTERIDE; HISTONE DEACETYLASE INHIBITOR; METRIBOLONE; STEROID 5ALPHA REDUCTASE; TRICHOSTATIN A; ANDROGEN; CHOLESTEROL MONOOXYGENASE (SIDE CHAIN CLEAVING); MESSENGER RNA; PRIMER DNA; SERINE PROTEINASE; STEROID; TMPRSS2 PROTEIN, HUMAN;

ANDROGEN METABOLISM; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE; CELL STRAIN DUCAP; CELL VIABILITY; CONTROLLED STUDY; ELECTRORETINOGRAM; ERYTHROCYTE; HORMONAL THERAPY; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; ANIMAL; CELL SURVIVAL; DISEASE COURSE; FLUORESCENCE IN SITU HYBRIDIZATION; GENETICS; METABOLISM; METHODOLOGY; MOUSE; MOUSE MUTANT; PATHOLOGY; POLYMERASE CHAIN REACTION; PROSTATE TUMOR; TUMOR CELL LINE;

ANDROGEN ANTAGONISTS; ANDROGENS; ANIMALS; APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; CELL SURVIVAL; CHOLESTEROL SIDE-CHAIN CLEAVAGE ENZYME; DISEASE PROGRESSION; DNA PRIMERS; FINASTERIDE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MICE; MICE, SCID; POLYMERASE CHAIN REACTION; PROSTATIC NEOPLASMS; RNA, MESSENGER; SERINE ENDOPEPTIDASES; STEROIDS;

EID: 77956991997     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21187     Document Type: Article

References (33)

1. Huggins C, Hodges CV,. Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA Cancer J Clin 1972; 22: 232 -240.
2. Goktas S, Ziada A, Crawford ED,. Combined androgen blockade for advanced prostatic carcinoma. Prostate Cancer Prostatic Dis 1999; 2: 172 -179. (Pubitemid 30055530)
3. Mostaghel EA, Page ST, Lin DW, Fazli L, Coleman IM, True LD, Knudsen B, Hess DL, Nelson CC, Matsumoto AM, Bremner WJ, Gleave ME, Nelson PS,. Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: Therapeutic implications for castration-resistant prostate cancer. Cancer Res 2007; 67: 5033 -5041.
4. Mohler JL, Gregory CW, Ford OH III, Kim D, Weaver CM, Petrusz P, Wilson EM, French FS,. The androgen axis in recurrent prostate cancer. Clin Cancer Res 2004; 10: 440 -448.
5. Nishiyama T, Hashimoto Y, Takahashi K,. The influence of androgen deprivation therapy on dihydrotestosterone levels in the prostatic tissue of patients with prostate cancer. Clin Cancer Res 2004; 10: 7121 -7126. (Pubitemid 39487695)
6. Titus MA, Schell MJ, Lih FB, Tomer KB, Mohler JL,. Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. Clin Cancer Res 2005; 11: 4653 -4657.
7. Holzbeierlein J, Lal P, LaTulippe E, Smith A, Satagopan J, Zhang L, Ryan C, Smith S, Scher H, Scardino P, Reuter V, Gerald WL,. Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am J Pathol 2004; 164: 217 -227.
8. Stanbrough M, Bubley GJ, Ross K, Golub TR, Rubin MA, Penning TM, Febbo PG, Balk SP,. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res 2006; 66: 2815 -2825.
9. Montgomery RB, Mostaghel EA, Vessella R, Hess DL, Kalhorn TF, Higano CS, True LD, Nelson PS,. Maintenance of intratumoral androgens in metastatic prostate cancer: A mechanism for castration-resistant tumor growth. Cancer Res 2008; 68: 4447 -4454.
10. Locke JA, Guns ES, Lubik AA, Adomat HH, Hendy SC, Wood CA, Ettinger SL, Gleave ME, Nelson CC,. Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res 2008; 68: 6407 -6415.
11. Dillard PR, Lin MF, Khan SA,. Androgen-independent prostate cancer cells acquire the complete steroidogenic potential of synthesizing testosterone from cholesterol. Mol Cell Endocrinol 2008; 295: 115 -120.
12. Lee YG, Korenchuk S, Lehr J, Whitney S, Vessela R, Pienta KJ,. Establishment and characterization of a new human prostatic cancer cell line: DuCaP. In Vivo 2001; 15: 157 -162.
13. van Bokhoven A, Varella-Garcia M, Korch C, Johannes WU, Smith EE, Miller HL, Nordeen SK, Miller GJ, Lucia MS,. Molecular characterization of human prostate carcinoma cell lines. Prostate 2003; 57: 205 -225. (Pubitemid 37267805)
14. Saramaki OR, Harjula AE, Martikainen PM, Vessella RL, Tammela TL, Visakorpi T,. TMPRSS2: ERG fusion identifies a subgroup of prostate cancers with a favorable prognosis. Clin Cancer Res 2008; 14: 3395 -3400.
15. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, Varambally S, Cao X, Tchinda J, Kuefer R, Lee C, Montie JE, Shah RB, Pienta KJ, Rubin MA, Chinnaiyan AM,. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005; 310: 644 -648.
16. Kumar-Sinha C, Tomlins SA, Chinnaiyan AM,. Recurrent gene fusions in prostate cancer. Nat Rev Cancer 2008; 8: 497 -511.
17. de Bruijn DR, Kater-Baats E, Eleveld M, Merkx G, Geurts Van KA,. Mapping and characterization of the mouse and human SS18 genes, two human SS18-like genes and a mouse Ss18 pseudogene. Cytogenet Cell Genet 2001; 92: 310 -319.
18. Bjorkman M, Iljin K, Halonen P, Sara H, Kaivanto E, Nees M, Kallioniemi OP,. Defining the molecular action of HDAC inhibitors and synergism with androgen deprivation in ERG-positive prostate cancer. Int J Cancer 2008; 123: 2774 -2781.
19. Moser FG, Dorman BP, Ruddle FH,. Mouse-human heterokaryon analysis with a 33258 Hoechst-Giemsa technique. J Cell Biol 1975; 66: 676 -680.
20. Linja MJ, Savinainen KJ, Saramaki OR, Tammela TL, Vessella RL, Visakorpi T,. Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res 2001; 61: 3550 -3555. (Pubitemid 32694958)
21. Sedelaar JP, Isaacs JT,. Tissue culture media supplemented with 10% fetal calf serum contains a castrate level of testosterone. Prostate 2009; 69: 1724 -1729.
22. Feldman BJ, Feldman D,. The development of androgen-independent prostate cancer. Nat Rev Cancer 2001; 1: 34 -45.
23. Kokontis J, Takakura K, Hay N, Liao S,. Increased androgen receptor activity and altered c-myc expression in prostate cancer cells after long-term androgen deprivation. Cancer Res 1994; 54: 1566 -1573.
24. Joly-Pharaboz MO, Soave MC, Nicolas B, Mebarki F, Renaud M, Foury O, Morel Y, Andre JG,. Androgens inhibit the proliferation of a variant of the human prostate cancer cell line LNCaP. J Steroid Biochem Mol Biol 1995; 55: 67 -76.
25. Whitacre DC, Chauhan S, Davis T, Gordon D, Cress AE, Miesfeld RL,. Androgen induction of in vitro prostate cell differentiation. Cell Growth Differ 2002; 13: 1 -11.
26. Morris MJ, Huang D, Kelly WK, Slovin SF, Stephenson RD, Eicher C, Delacruz A, Curley T, Schwartz LH, Scher HI,. Phase 1 trial of high-dose exogenous testosterone in patients with castration-resistant metastatic prostate cancer. Eur Urol 2009; 56: 237 -244.
27. Szmulewitz R, Mohile S, Posadas E, Kunnavakkam R, Karrison T, Manchen E, Stadler WM,. A randomized phase 1 study of testosterone replacement for patients with low-risk castration-resistant prostate cancer. Eur Urol 2009; 56: 97 -104.
28. Pfeiffer MJ, Schalken JA,. Stem cell characteristics in prostate cancer cell lines. Eur Urol 2010; 57: 246 -254.
29. Small EJ, Ryan CJ,. The case for secondary hormonal therapies in the chemotherapy age. J Urol 2006; 176: S66 -S71.
30. Attard G, Reid AH, A'hern R, Parker C, Oommen NB, Folkerd E, Messiou C, Molife LR, Maier G, Thompson E, Olmos D, Sinha R, Lee G, Dowsett M, Kaye SB, Dearnaley D, Kheoh T, Molina A, de Bono JS,. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol 2009; 27: 3742 -3748.
31. Van Allen EM, Ryan CJ,. Novel secondary hormonal therapy in advanced prostate cancer: An update. Curr Opin Urol 2009; 19: 315 -321.
32. Welsbie DS, Xu J, Chen Y, Borsu L, Scher HI, Rosen N, Sawyers CL,. Histone deacetylases are required for androgen receptor function in hormone-sensitive and castrate-resistant prostate cancer. Cancer Res 2009; 69: 958 -966.
33. Niu YN, Xia SJ,. Stroma-epithelium crosstalk in prostate cancer. Asian J Androl 2009; 11: 28 -35.